NVO Novo Nordisk A/S
Novo Nordisk A/S (NVO) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. If this ticker has no settled sample yet, treat the numbers as a geometric read, not a track record. Information only, not financial advice.
Mid-channel
Price is between the two trend lines. Nothing to act on yet.
Read from the last 2 years of history we hold: falling, drifting −41% a year. The nearest ceiling overhead is US$48.12. What would overturn this: a close below US$24.17 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 2 years read from
- US$24.17 – US$48.12 Falling channel, −41% a year
- Position in that channel
- 73% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call today because its projected path only reaches 0.1% above the entry within 90 days, under the 6.0% floor a call has to clear to be worth making. No alerts are sent. The buy and target below are still this site's read of the fitted channel.
Buy at or below
US$24.05
level as at 17 Sept 2026
Our target
US$43.52
by 16 Dec 2026
Projected move
81.0%
gross, before costs
Price sits between our buy level and our target.
- Upper line touches
- 5
- Lower line touches
- 6
- Fit confidence
- 41%
- Fitted
- 11 Sept 2026
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar
- Employees
- 68,794
- Country
- DK
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$191.26B
- Enterprise value
- —
- Beta
- 0.35
- Avg volume
- 12.51M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 35.12-64.16
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.